Despite two decades of clinical experience with Everolimus in transplant medicine, cancer patients continue to face ...

START and OneOncology are launching three new early-phase cancer trial sites in California, Texas, and New Jersey, expanding access in community settings where 70% of patients receive care.

IMUNON’s Phase 2 OVATION 2 trial of IMNN-001 in advanced ovarian cancer showed a 13-month OS increase (46 vs. 33 months) and ...

ONCOLife presents an exclusive interview with Sarah Hein, CEO of March Biosciences. In this session, we explore clinical ...

The START Center for Cancer Research dosed the first patient in Moderna’s Phase 1 trial of mRNA-4106, a multivalent ...

The FDA granted accelerated approval to Emrelis (telisotuzumab vedotin-tllv), the first targeted therapy for previously ...

Lumipulse G pTau217/β-Amyloid 1-42—for the diagnosis of Alzheimer’s disease. It demonstrated 91.7% sensitivity and 97.3% ...

ONCOLife is delighted to announce that Dr İlkiz Er Dağ, MD, MBA, has joined the company as Project Director for Oncology ...

The European Commission has approved a perioperative regimen of Bristol Myers Squibb’s immunotherapy drug Opdivo® (nivolumab) ...

The V Foundation for Cancer Research, a top-rated cancer charity, announced an exciting partnership with Cancer Vaccine ...

ONCOLife presents an exclusive interview with Nick Slack, Chairman and CEO of The START Center for Cancer Research. In this session, we explore how the integration of the Carolina Urologic Research ...

New 10-year results from the APHINITY trial show that adding pertuzumab (Perjeta®) to trastuzumab (Herceptin®) and ...